Roche agreed on October 19, 2026 to pay Hansoh Pharma $400 million upfront and over $15 billion in potential milestones for ADCs built on its platform.
Last updated: October 20, 2026
Roche signed a collaboration and license agreement with Hansoh Pharma on October 19, 2026 covering two preclinical Hansoh antibody drug conjugates plus multiple ADCs aimed at targets Roche chooses, built on Hansoh’s proprietary platform. Hansoh receives $400 million upfront, $110 million on the first anniversary, more than $15 billion in potential milestones, and tiered royalties, and keeps Greater China rights.
Scope: deal terms, trial results, approvals, and market data from Monday, October 19, 2026, with primary sources named for every figure.
What did Roche agree to pay Hansoh for its ADC platform?
Roche committed $400 million upfront and $110 million at the first anniversary, with more than $15 billion in development, regulatory, and commercial milestones and tiered royalties on sales, according to Hansoh’s October 19 release. The deal licenses the output of Hansoh’s ADC platform, not the platform itself.
| Term | Detail (Hansoh release, Oct 19, 2026) |
|---|---|
| Upfront payment | $400 million |
| First anniversary payment | $110 million |
| Milestones | Potentially more than $15 billion (development, regulatory, commercial) |
| Royalties | Tiered, on future net sales |
| Programs | Two preclinical Hansoh ADC programs plus multiple ADC programs on Roche proposed targets (targets not disclosed) |
| Who develops early | Hansoh, through completion of global Phase Ia trials |
| Roche territory | Worldwide excluding mainland China, Hong Kong, Macau, and Taiwan |
| Hansoh retained rights | All rights in mainland China, Hong Kong, Macau, and Taiwan |
| Hansoh option | May select up to two programs to contribute to development outside China, for incremental upside from US commercialization |
| Closing conditions | None stated in the release |
Endpoints News characterized the agreement as Roche’s sixth China deal since August. The release does not mention export controls or any Chinese government approval.
How does the Roche Hansoh deal fit China’s draft biotech export controls?
It sits squarely inside the lane the draft leaves open. As reported by Fierce Biotech on October 16, China’s commerce ministry draft would ban foreign acquisition of proprietary platforms in cell and gene therapy, siRNA, and pathogen gain of function research, while excluding out licensing from the restrictions. Comments close November 15.
Monday produced three platform deals on the first business day after the draft surfaced, and they split cleanly along the line the draft draws between renting output and owning the engine.
| Deal (Oct 19, 2026) | Structure | Platform ownership changes hands? | Headline value | Source |
|---|---|---|---|---|
| Roche and Hansoh Pharma | License and collaboration on ADCs | No; Hansoh keeps the platform and Greater China | $400M upfront; more than $15B milestones | Hansoh release (primary) |
| Eli Lilly and Metis TechBio | Discovery collaboration on AI designed lipid nanoparticles | No | Up to about $1.1B; upfront in the low double digit millions | Fierce Biotech, Reuters, Minichart (Metis exchange filing not fetched) |
| Merck KGaA and Silence Therapeutics | Full acquisition by UK scheme of arrangement | Yes; a UK siRNA platform company is bought outright | $20.00 per ADS; equity value about $1.3B | Silence release (primary) |
The draft’s scope comes from Fierce Biotech’s reporting of the document; our own fetch of the draft text has not succeeded. Our earlier coverage of the draft is linked under related coverage below.
What is Merck KGaA paying for Silence Therapeutics?
Merck KGaA, Darmstadt, Germany agreed to pay $20.00 in cash per Silence American depositary share, an equity value of about $1.3 billion and an enterprise value of $1.1 billion, according to the companies’ October 19 release. Closing is expected in the first quarter of 2027.
| Term | Detail (Silence release, Oct 19, 2026) |
|---|---|
| Price | $20.00 cash per ADS (each ADS = three ordinary shares) |
| Equity value | About $1.3 billion |
| Enterprise value | $1.1 billion |
| Premium | 130% to the October 16 ADS close; 82% to the 30 day VWAP of $10.99 |
| Structure | UK scheme of arrangement (Part 26, Companies Act 2006) |
| Conditions | Silence shareholder approval, High Court sanction, regulatory approvals |
| Support | Holders of about 14% of voting power signed support agreements |
| Expected close | First quarter of 2027 |
The lead asset is divesiran, an siRNA that silences TMPRSS6 to raise hepcidin and restrict iron for red cell production in polycythemia vera. Fierce Biotech reported that 88% of Phase 2 patients met response criteria between weeks 18 and 36, and that Silence plans dosing every 12 weeks, against the weekly injection used for Takeda and Protagonist’s Mimrylo, approved in August 2026. Fierce also noted that Hansoh had exited Silence’s zerlasiran collaboration and AstraZeneca had returned SLN312 rights earlier this year.
What did Disc Medicine’s APOLLO Phase 3 trial show?
Bitopertin met both co primary endpoints and every secondary endpoint in APOLLO, Disc Medicine’s pivotal trial in erythropoietic protoporphyria, according to the company’s October 19 release. Disc plans to resubmit its NDA by the end of 2026 and anticipates an FDA decision by mid 2027.
| APOLLO measure (n=183, ages 12 and up, 6 months) | Bitopertin 60 mg vs placebo | p value |
|---|---|---|
| Whole blood metal free PPIX, change from baseline (co primary) | −41.4% | <0.0001 |
| Monthly time in light without pain, month 6 (co primary) | +12.2 hours | 0.0010 |
| Phototoxic reaction rate over 6 months | Reduced | <0.0001 |
| Cumulative time in light without pain | Increased | <0.0001 |
| Daily sunlight exposure to prodrome (adults) | Increased | 0.0077 |
| Most common adverse event | Dizziness, 50% of bitopertin patients, mostly mild or moderate and transient | n/a |
The release reported no treatment emergent adverse events above Grade 3 and said detailed data will go to a future medical meeting. The trial pairs a biomarker endpoint with a functional one, which is the evidence package Disc’s resubmission rests on after the FDA’s earlier complete response letter.
What did Veradermics’ Phase 3 study 304 show for oral minoxidil?
VDPHL01, an extended release oral minoxidil, beat placebo on both co primary endpoints at month 6 in 536 men with mild to moderate pattern hair loss, with p<0.0001 across primary and secondary endpoints, according to Veradermics’ October 19 release. Study 304 is a new trial, distinct from the earlier study 302.
| Study 304, month 6 | 8.5 mg once daily | 8.5 mg twice daily | Placebo |
|---|---|---|---|
| Non vellus target area hair count, mean increase (hairs/cm²) | 28.6 | 36.4 | 6.6 |
| Patient rated “improved” or “much improved” (AAIRS) | 55.7% | 68.7% | 15.0% |
| Peripheral edema | 2.8% | 4.5% | 0.6% |
| Hypertrichosis | 2.2% | 9.0% | 0% |
Separation from placebo appeared as early as month 2. Veradermics reported no treatment related serious adverse events and no cardiac adverse events of special interest. The release gives no NDA timing; 12 month safety data from study 302 Part B are due later this year and the female study 306 topline in the first half of 2027.
Why does the Jemperli approval in rectal cancer matter?
The FDA granted accelerated approval on October 19 to GSK’s Jemperli (dostarlimab-gxly) as a single agent for adults with stage II or III, locally advanced rectal cancer that is MSI-H/dMMR, making it the first immunotherapy for this setting, according to GSK. Most responders in AZUR-1 avoided surgery.
| AZUR-1 measure | Result |
|---|---|
| Design | Single arm Phase 2, 154 patients, nine cycles over six months |
| Sustained clinical complete response at 12 months, investigator assessed | 68% (98/144) |
| Same endpoint, independent central review (data maturing) | 47% (54/116) |
| No evidence of cancer at one year or more (exploratory) | 76% (110/144) |
| Recurrences among responders | None reported; median follow up more than two years |
Continued approval may depend on a confirmatory trial. The release crossed after Monday’s close, so Tuesday is GSK’s first reaction session.
What did the FDA clear for Sequel’s twiist insulin system?
Sequel Med Tech disclosed on October 16 that the FDA cleared its twiist automated insulin delivery system for adults with insulin treated Type 2 diabetes, extending a March 2024 Type 1 clearance, as reported by MedTech Dive and Healio. The 510(k) went to Sequel’s partner, DEKA Research and Development.
In a 13 week trial of 307 adults, A1C fell 0.7 percentage points and time in range rose from 57% to 73%, per Healio’s report. The system runs on the Tidepool Loop algorithm and pairs with Abbott’s FreeStyle Libre 3 Plus and Senseonics’ Eversense 365. It enters a Type 2 market where Insulet, Tandem, Beta Bionics, and the newly independent MiniMed already compete.
Which life sciences stocks moved on Monday’s news?
Five moves carried a story on Monday, October 19, a session when the SPDR S&P Biotech ETF (XBI) closed at 147.86, up 2.5%. Percentages are our arithmetic from settled exchange closes against Friday, October 16.
| Ticker | Close Oct 19 | Change | Context |
|---|---|---|---|
| Silence Therapeutics (SLN) | $19.58 | +125.6% | Merck KGaA cash offer of $20.00 per ADS; closed 2.1% below the offer |
| Disc Medicine (IRON) | $78.93 | +38.9% | APOLLO met all primary and secondary endpoints |
| Veradermics (MANE) | $122.28 | +12.4% | Study 304 positive topline |
| Iambic Therapeutics (IAM) | $16.34 | −31.4% | No company disclosure found; traded as low as $14.10 intraday, below the $16.00 IPO price, before closing 2.1% above it |
| MiniMed (MMED) | $17.79 | +1.7% | Second post separation session; exchange package value (4.5939 shares) $81.73, 11.9% below Medtronic’s $92.77 close |
Frequently asked questions
How much is Roche paying Hansoh upfront?
Roche is paying Hansoh $400 million upfront plus $110 million on the agreement’s first anniversary, according to Hansoh’s October 19, 2026 release.
What is the total potential value of the Roche Hansoh ADC deal?
Hansoh is eligible for more than $15 billion in development, regulatory, and commercial milestones on top of the upfront and anniversary payments, plus tiered royalties on sales.
Does Roche acquire Hansoh’s ADC platform?
No. Roche licenses programs built on the platform, including ADCs against targets Roche proposes. Hansoh keeps the platform and all rights in mainland China, Hong Kong, Macau, and Taiwan.
Would China’s draft export controls block a deal like Roche and Hansoh?
Based on Fierce Biotech’s reporting of the draft, out licensing is excluded from the restrictions, which target foreign acquisition of certain platforms. A license that leaves platform ownership in China appears to fall outside the ban. The final rules are not out; comments close November 15.
Which ADC targets are in the Roche Hansoh deal?
The release does not name them. It describes two preclinical Hansoh programs and multiple programs on targets Roche proposes.
How much is Merck KGaA paying for Silence Therapeutics?
$20.00 in cash per ADS, an equity value of about $1.3 billion and an enterprise value of $1.1 billion. The price is a 130% premium to Silence’s October 16 close.
When will the Merck KGaA Silence deal close?
The companies expect closing in the first quarter of 2027, subject to shareholder approval, UK High Court sanction, and regulatory approvals.
What is divesiran?
Divesiran is Silence’s siRNA that silences TMPRSS6 to raise hepcidin and limit iron for red blood cell production, in development for polycythemia vera.
Did bitopertin succeed in Phase 3?
Yes. In APOLLO, bitopertin cut whole blood PPIX 41.4% versus placebo and added 12.2 hours of monthly time in light without pain at month 6, meeting both co primary endpoints and all secondary endpoints.
When could the FDA approve bitopertin?
Disc plans to resubmit its NDA by the end of 2026 and anticipates an FDA decision by mid 2027.
What side effects did bitopertin show in APOLLO?
Dizziness was the most common adverse event, in 50% of bitopertin patients, mostly mild or moderate and transient. No adverse events above Grade 3 were reported.
How well did oral minoxidil VDPHL01 work in study 304?
At month 6, the twice daily dose added 36.4 non vellus hairs per cm² and the once daily dose 28.6, versus 6.6 on placebo, with p<0.0001.
Is Jemperli now approved for rectal cancer?
Yes. The FDA granted accelerated approval on October 19, 2026 for adults with stage II or III, MSI-H/dMMR locally advanced rectal cancer, based on a 68% sustained clinical complete response rate at 12 months in AZUR-1.
Can Type 2 diabetes patients use the twiist insulin system?
Yes. The FDA cleared twiist for adults with insulin treated Type 2 diabetes, disclosed by Sequel on October 16, 2026.
Sources
Primary (company releases, October 19, 2026): Hansoh Pharma, “Hansoh Pharma Announces Strategic Collaboration and License Agreement with Roche to Advance Novel ADC Portfolio” (hspharm.com); Silence Therapeutics, “Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany” (Business Wire); Disc Medicine, “Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial” (ir.discmedicine.com); Veradermics, “Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial” (ir.veradermics.com); GSK, “Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer” (us.gsk.com).
Trade press (attributed): Fierce Biotech, October 19 (Merck KGaA and Silence context; Lilly and Metis); Fierce Biotech, October 16 (China draft export controls); Endpoints News, October 19 (Roche China deal count); Reuters via TradingView and Minichart, October 19 (Metis terms); MedTech Dive, October 19, and Healio, October 16 (Sequel twiist).
Market data: Settled exchange closes, October 16 and October 19, 2026; percentage changes are our arithmetic.
